Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer
Source: OncLive, July 2021
The combination of the galactin-3 inhibitor belapectin (GR-MD-02) plus pembrolizumab (Keytruda) has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer, according to topine data from an extension cohort of an investigator-initiated phase 1b trial (NCT02575404).1
